An inexpensive home meter to monitor CKD and heart failure directly in a drop of blood

一种廉价的家用仪表，可直接通过一滴血监测 CKD 和心力衰竭

• 批准号: 531930-2018
• 负责人: ValléeBélisle, Alexis
• 金额: $ 12.75万
• 依托单位: Université de Montréal
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=719723
• 关键词: inexpensive; home; meter; monitor; CKD

Empowering patients to make timely and appropriate decisions regarding their health can fundamentally change the consumption of healthcare. For example, recent advances in continuous glucose monitoring have enabled insulin-dependent diabetes patients to titrate their insulin dosing and hence achieve tighter glycemic control in a sustained manner. There is an opportunity to drive similar diagnostic-based disruption in Chronic Kidney Disease (CKD), Heart Failure (HF) and even inflammation or immune response mediated diseases such as Coronary Vascular Disease (CVD) and celiac disease (CD). The Vallée-Bélisle lab at the University of Montreal recently reported and patented a family of electrochemical DNA-based assays that can deliver lab quality measurements at home from one drop of whole blood, thereby enabling the patient to titrate its therapy in real-time. The proposed project will provide scientific and engineering evidence establishing the technical feasibility to develop a prototype electrochemical DNA-based sensor and will develop this prototype for the detection of 3 key markers for monitoring CKD and HF at home.

使患者能够就自己的健康做出及时、适当的决定可以从根本上改变医疗保健的消费，例如，连续血糖监测的最新进展使胰岛素依赖型糖尿病患者能够调整胰岛素剂量，从而持续实现更严格的血糖控制。有机会在慢性肾脏病（CKD）、心力衰竭（HF）甚至炎症或免疫反应介导的疾病（例如冠状血管疾病（CVD）和乳糜泻（CD））中推动类似的基于诊断的破坏。蒙特利尔大学的 Vallée-Bélisle 实验室最近报告了一系列基于 DNA 的电化学检测并获得了专利，这些检测可以在家中通过一滴全血进行实验室质量测量，从而使患者能够实时滴定其治疗。拟议项目将提供科学和工程证据，确定开发基于电化学 DNA 的传感器原型的技术可行性，并将开发该原型用于检测 3 个关键标记物，以在家中监测 CKD 和 HF。